Neovascular Age-related Macular Degeneration
Conditions
Brief summary
REALIZE was a single-arm retrospective cohort study which described treatment patterns with brolucizumab, including treatment intervals between anti-vascular endothelial growth factor (VEGF) injections before and after a switch to brolucizumab. This study was conducted using German patient-level prescription data and the prescription date was used as a proxy for anti-VEGF injection date. The study period was defined from the date of the first available anti-VEGF injection in the dataset to 30 November 2021. The index date for each patient was the date of the first brolucizumab injection, which could be anytime between 01 March 2020 (since brolucizumab became available in Germany for use outside of clinical trials in March 2020) and 30 November 2021. The date of the patient's first neovascular age-related macular degeneration (nAMD) diagnosis was assumed to be the date of the first anti-VEGF prescription in the database for that patient, from January 2015 onwards.
Interventions
None listed
Sponsors
Novartis Pharmaceuticals
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
• Patients aged ≥50 years with a nAMD diagnosis, who received ≥1 brolucizumab prescription regardless of prior anti-VEGF treatment, and had a minimum of 12-month follow-up from index date.
Exclusion criteria
* Patients without a record of prescription of any drug in the six months before the index date (pre-index period). * Patients with evidence of bilateral treatment with brolucizumab.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of brolucizumab injections | Up to 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Time difference between the last anti-VEGF treatment interval before switch to brolucizumab and the last brolucizumab treatment interval at 12 months | Up to 12 months |
Countries
Portugal
Outcome results
None listed